Factors influencing remission phase in children with type I diabetes mellitus

Journal of Pediatric Endocrinology and Metabolism

Volumn 14, Issue 9, 2001, Pages 1585-1596

  Buyukgebiz A ^a   Cemeroglu, A P ^a   Bober E ^a   Mohn, A ^a   Chiarelli, F ^a  

^a Policlinico   (Italy)

Author keywords

Nicotinamide; Prevention trials; Related factors; Remission phase; Type 1 diabetes mellitus

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BCG VACCINE; CD31 ANTIGEN; CYCLOSPORIN; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN; INDOMETACIN; INSULIN; LYMPHOCYTE ANTIBODY; NICOTINAMIDE DERIVATIVE; PREDNISONE; STEROID; STREPTOZOCIN; THYMOPOIETIN; THYMOSTIMULIN;

ADOLESCENT; AGE; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; CELL DESTRUCTION; CHILD; CONTROLLED STUDY; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HLA TYPING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MOUSE; NONHUMAN; PANCREAS CELL; PANCREAS FUNCTION; PUBERTY; REMISSION; RISK FACTOR; SEX DIFFERENCE; TREATMENT PLANNING;

AGING; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INSULIN; ISLETS OF LANGERHANS; PUBERTY; REMISSION, SPONTANEOUS; SEX CHARACTERISTICS;

EID: 0035677504     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Partial remission phase of diabetes in children younger than age 10 years
2. Factor predicting clinical remission in adult patients with type 1 diabetes
3. Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: The role of puberty
4. Sustained normoglycemia in newly diagnosed type 1 diabetic subjects. Short-term effects and one-year follow-up
5. Management of the child with diabetes mellitus. Clinical course, therapeutic strategies and monitoring techniques
6. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual beta cell function
7. Does the long-term clinical course of type 1 diabetes mellitus differ in patients with prepubertal and pubertal onset? Results of the Berlin Retinopathy Study
8. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI)
9. Partial remission phase and metabolic control in insulin dependent diabetes mellitus in children and adolescents
10. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr
11. Age governs gender-dependent islet cell autoreactivity and predicts the clinical course in childhood IDDM
12. Remission in IDDM: Prospective study of basal C-peptide and insulin dose in 268 consecutive patients
13. C-peptide revisited - New physiological effects and therapeutic implications
14. Does C-peptide have a physiologic role?
15. Postinitial remission in diabetic children - An analysis of 178 cases
16. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with type 1 diabetes mellitus
17. Seven years of remission in a type 1 diabetic patient
18. Impact of physiologic fitness and glycemic control on in vivo insulin action in adolescents with IDDM
19. Sexual dimorphism in insulin sensitivity in adolescents with insulin-dependent diabetes mellitus
20. Preservation of β-cell function in type 1 diabetes
21. Interaction of beta-cell activity and IL-concentration and exposure time in isolated rat islets of Langerhans
22. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial
23. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus
24. Insulin prophylaxis in individuals at high risk of type 1 diabetes
25. Insulin dependent diabetes mellitus as an autoimmune disease
26. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone-marrow transplant
27. Autoimmune polyendocrine failure - Type 1 (insulin-dependent) diabetes mellitus and hypothyroidism - After allogeneic bone marrow transplantation in a patient with lymphoblastic leukaemia
28. T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM
29. Insulin autoantibodies: Their role in the pathogenesis of IDDM
30. Are insulin autoantibodies markers for insulin-dependent diabetes mellitus?
31. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins
32. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes mellitus
33. Negative correlation between ICA persistence and β-cell restoration after IDDM diagnosis
34. Age-corrected empirical genetic risk estimates for first degree relatives of IDDM patients
35. Family history and risk of insulin dependent diabetes mellitus: A population-based case-control study
36. Diabetes in identical twins. A study of 200 pairs
37. HLA-DR typing in identical twins with insulin dependent diabetes, difference between concordant and discordant pairs
38. Indications for a more aggressive disease process in newly diagnosed insulin-dependent diabetic children in northern than southern Europe
39. Natural course of remission in IDDM during 1st year after diagnosis
40. Evidence of an accelerated β-cell destruction in HLA DW3/DW4 heterozygous children with type 1 (insulin dependent) diabetes
41. Effect of genetic risk load defined by HLA-DQB1 polymorphism on clinical characteristics of IDDM in children
42. Cyclosporin increases the rate and length of remission in insulin-dependent diabetes of recent onset. Results of a multicenter double-blind trial
43. Limited duration of remission of insulin dependency in children with recent over type 1 diabetes treated with low-dose cyclosporin
44. Lack of predictive value of islet cell antibodies, insulin antibodies and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients
45. Plasma C-peptide levels and clinical remission in recent onset type 1 diabetic patients treated with cyclosporin A and insulin
46. Comparison of high dose immunoglobulin and cyclosporin in newly diagnosed diabetic children
47. Effect of cyclosporin A treatment on the production of antibody in insulin dependent (type 1) diabetic patients
48. Cyclosporin A for the treatment of new-onset insulin-dependent diabetes mellitus
49. Increase in remission rate in newly diagnosed type 1 diabetic subjects treated with azathioprine
50. Double-blind controlled trial of azathioprine in children with newly diagnosed type 1 diabetes
51. Insulin requirements and residual β-cell function 12 months after concluding immunotherapy in type 1 diabetic patients treated with combined azathioprine and thymostimulin administration for one year
52. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus
53. Effects of a short prednisone regime at clinical onset of type 1 diabetes
54. Prednisone treatment in newly diagnosed type 1 diabetic children: 1-year follow-up
55. Prednisone administration in recent onset type 1 diabetes
56. Long-term results of intravesical Bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer
57. Weekly mitomycin C followed by monthly Bacillus Calmette-Guerin or alternating monthly interferon-α2B and Bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma
58. BCG vaccine prevents insulinitis in low dose streptozotocin-induced diabetic mice
59. Immunization in the first month of life may explain decline in incidence of IDDM in the Netherlands
60. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study
61. Effect of Bacillus Calmette-Guerin vaccination on C-peptide secretion in children newly diagnosed with IDDM
62. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus
63. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice
64. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum
65. Immunospecific therapy for type 1 diabetes mellitus
66. Early administration of an immuno-modulator and induction of remission in insulin-dependent diabetes mellitus
67. Intervention at diagnosis of type 1 diabetes using either antioxidants or photopheresis
68. Influence of nicotinamide and pyridine nucleotides on streptozocin and alloxan-induced pancreatic B cell cytotoxicity
69. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulinitis: An observation in nonobese diabetic (NOD) mice
70. Theory and practice of nicotinamide trials in pre-type 1 diabetes
71. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus
72. Early intensification of treatment in diabetes using a combination of insulin and nicotinamide - Effect on C- peptide levels and the course of the disease
73. A preliminary multicentre study of the treatment of recently diagnosed type 1 diabetes by combination nicotinamide-cyclosporin therapy
74. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1)